GSK's fastest-growing division put in a standout quarter, but the market's attention settled on a smaller decline in vaccines, and the shares lost nearly a twentieth of their value in a day.
Two numbers framed the reaction to GSK's third-quarter results on Wednesday 28 October 2026: a 15% rise in Specialty Medicines sales and a 2% fall in vaccines, both at constant exchange rates. The first was the bigger move. The second proved the more influential. GSK (LSE:GSK) shares fell 4.78% to 1,831.50p, one of the heaviest declines in a FTSE 100 that closed only 7.96 points higher at 10,694.50.
Reports said GSK's sales and earnings had beaten forecasts, but that vaccines contributed less than consensus had expected and that investors were not convinced by the company's push to build its pipeline. Understanding why a modest dip could outweigh a big surge requires a closer look at how GSK's business is put together.
Three divisions, three different stories
GSK reported third-quarter turnover of £8.9bn, up 5% at constant exchange rates (CER) and 4% at actual exchange rates. That total breaks down across three divisions:
- Specialty Medicines: £3.9bn, up 15% at CER
- Vaccines: £2.6bn, down 2% at CER
- General Medicines: £2.4bn, broadly stable
Seen this way, Specialty Medicines is the largest division and the clear growth engine. Vaccines, however, still accounts for close to three in every ten pounds of sales, which means a shortfall there matters to the group's overall picture.
General Medicines, the third leg, was broadly stable at £2.4bn. A flat division neither adds to nor subtracts much from group growth, which places more of the burden of explaining the quarter on the other two. With one division racing ahead and another slipping, the group total of 5% growth at CER effectively masks two very different trends, and investors had to decide which one deserved more weight in the short term.
Why the smaller move mattered more
The market's reaction rests on the difference between results and expectations. Analysts build forecasts for each division, and share prices tend to reflect those forecasts before results are published. If one part of the business comes in below expectations, the shortfall can outweigh good news elsewhere, especially if the good news was already anticipated.
According to reports, vaccines contributed less than consensus. Within the division, Shingrix sales were £0.8bn, down 5% at CER. £0.8bn out of £2.6bn means Shingrix represented just under a third of vaccines sales in the quarter, so its decline carried weight for the division as a whole.
Vaccine sales can be shaped by factors such as public health programmes, seasonal patterns and the timing of orders, which can make them less predictable from quarter to quarter than some other product lines.
GSK is continuing to invest in vaccines. During the quarter it started a phase III trial of an mRNA seasonal flu vaccine, part of a wider programme in which it has made 18 of 22 planned phase III starts for 2026.
The Specialty story investors may revisit
Specialty Medicines' 15% growth at CER stood out as the best performance in the group. The quarter also brought several regulatory milestones. Jemperli was approved in the US for locally advanced dMMR/MSI-H rectal cancer, and Jideytro gained US approval for second-line ROS1-positive non-small cell lung cancer. Hibsago was approved in the US and Japan for chronic hepatitis B.
Each approval potentially broadens the range of products that could contribute to future sales, although the scale and timing of any contribution is uncertain. Chief executive Luke Miels described the period as another good quarter.
At the earnings level, core earnings per share rose 1% at CER to 54.6p, while total earnings per share fell 21% at CER to 38.5p. Core figures exclude certain items that management considers outside underlying performance, whereas total figures include them.
GSK reaffirmed its 2026 guidance at CER: turnover growth of 3–5%, toward the upper half of the range; core operating profit growth of 7–9%, also in the upper half; and core earnings per share growth of 7–9%, in the lower half. It also continues to pursue its Accelerate Growth programme, which targets £1.9bn of annual savings by 2029 at an expected total cost of £2.4bn.
The third-quarter dividend was 17p, with 70p expected for the full year. The £2bn buyback announced in FY2024 was completed in the second quarter, and no new programme was announced.
The share price fall weighed on a broader group. Market reports said that personal care, drug and grocery stocks fell nearly 1.4%, with Unilever (LSE:ULVR) down 2.05% after its own update. Meanwhile, banks rose 1.1% as a sector after the Budget's bank surcharge increase to 6% landed below feared levels. Before the results, GSK shares were up 27% over two years.
Key dates to watch
- Thu 29 Oct 2026: Haleon (LSE:HLN) publishes its Q3 trading statement, another healthcare-linked update in the FTSE 100.
- Fri 30 Oct 2026: AstraZeneca (LSE:AZN) reports Q3 results, a key comparison for divisional growth trends in UK pharma.
- Thu 5 Nov 2026: The Bank of England MPC decision and Monetary Policy Report, relevant to the wider index.
- Wed 2 Dec 2026: The FTSE December review announcement, after the close.
The bottom line
GSK's third quarter showed a company with a fast-growing Specialty Medicines business and a vaccines division that, for now, fell short of what analysts had hoped. The 15% Specialty surge was the larger move, but the 2% vaccines dip, and particularly the 5% fall in Shingrix sales, carried more weight with investors because it diverged from expectations. With guidance reaffirmed and several approvals secured, the question for the coming quarters is whether Specialty growth can continue to build while vaccines stabilise. Wednesday's 4.8% decline shows how closely the market will be watching both.
_11_16_2026_14_47_34_233787.jpg)





Please wait processing your request...